Retired Health Care Executive. ISPOR President 2023-24. Veteran. Colonel Commandant of the Royal Cdn Medical Svc. Former President & CEO of CADTH. Bruins fan.
Very pleased to be representing @ISPORorg at the @ICHOM2023 conference in Barcelona. 650 delegates from 46 countries attending the conference to share and learn about the important work being done by @ICHOM_ORG in developing core outcome sets.
Second plenary at #ISPOREurope is focused on real world use of patient-centred research, with a description of the Darwin EU initiative from the @EMA_News Many questions arise with Darwin, including whether it will be used to support both regulatory and reimbursement decisions.
Thank you to all of the participants of the 2022 ISPOR Health Technology Assessment Roundtable - Europe for an engaging and fruitful dialogue! Special thanks to the Chairs for their exceptional leadership and the speakers for their insightful presentations. #ISPOREurope#HTA
Announcing the release of the INAHTA Position Statement on Disruptive Technologies! This statement reflects members’ views on the concept of disruptive technologies – a topic of significant interest amongst the INAHTA membership. View full statement here: bit.ly/3cS5EjQ
Hey, fellow @ISPORorg members! It’s time to vote for your next president! Here’s a little video message from me about this election & videos from each of our two brilliant candidates: @jasminepwu and @ORourke_B
⬇️
ispor.org/about/our-leaders/…
The ballot is now open, so VOTE!!🗳️
Plenary 1: Rui Santos Ivo of @INFARMED_IP discusses an integrated approach and areas of action in scientific and regulatory advice including promoting timely access to medicines that introduce added value at a fair price, sustainable to NHS. #ISPOREurope#HTA
During the opening plenary at #ISPOREurope Dr. Hans-Georg Eichler stated that drugs with a small effect size and a small target population will have unavoidable uncertainty and that conventional HTA approaches will not be feasible. @ISPORorg
Opening plenary at #ISPOREurope Dr. Jo De Cock from INAMI Belgium describing a multi-stakeholder, international payer led initiative called RWE4Decisions. A key point mentioned by Dr. De Cock is that Outcomes-based MEAs should contain a clear RWE generation plan. @ISPORorg
ISPOR is thinking about many things, states @NbergBerg, including: Effectively communicating the value of #HEOR. Supporting #payers & decision makers. Digital transformation of #healthcare. Aligning HEOR and #technology. And more! #ISPOREurope
INAHTA and @HTAiOrg have renewed their Memoranda of Understanding, continuing a long & valuable relationship. The MOU, originally signed in 2008, was renewed in 2021 ensuring that MOU activities are ready for the future of HTA. Thank you HTAi, for being a great MOU partner!
Announcing the release of the INAHTA Position Statement on Patient Involvement ! This statement reflects INAHTA members’ views on the role of patient involvement in #HTA. View full statement here: bit.ly/3cS5EjQ#patientinvolvement
Dark day for FDA. Approving a drug on the basis of post-hoc analysis of a failed trial, in the context of a 2nd failed trial, a worrisome safety signal, and an exorbitant price. Promoting false hope for Alzheimer’s is not in the best interest of patients nytimes.com/2021/06/07/healt…